General Information of the Protein
Protein ID |
PT00892
|
||||
---|---|---|---|---|---|
Protein Name |
Tyrosine-protein kinase JAK3
|
||||
Secondarily Protein Name |
Janus kinase 3
Leukocyte janus kinase
|
||||
Gene Name |
JAK3
|
||||
Sequence |
MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKASGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGLRKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQRPGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIMDLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVDISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFCKEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNPLGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPKEKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCRHEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQEFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGADGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFSGVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSLISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Enzyme
>
Kinase
>
Protein Kinase
>
TK protein kinase group
>
Tyrosine protein kinase JakB family
|
||||
Function |
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A and STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Endomembrane system
Cytoplasm
|
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000077 , Ba/F3
Cell Line ID: CL000025 , HEK-293T
Cell Line ID: CL000006 , HEK293
Cell Line ID: CL000129 , HT-2
Cell Line ID: CL001000 , NMIi005-A
Cell Line ID: CL000752 , PBMC iPSC #1
Cell Line ID: CL000012 , Sf21
Cell Line ID: CL000013 , Sf9
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Janus kinase 3 (JAK-3) )
Target Type | Successful Target | ||||
---|---|---|---|---|---|
Disease | 9 Target-related Diseases | 9 | |||
1 | Rheumatoid arthritis [ICD-11: FA20] | ||||
2 | Myelofibrosis [ICD-11: 2A20.2] | ||||
3 | Atopic dermatitis [ICD-11: EA80] | ||||
4 | Alopecia areata [ICD-11: ED70.2] | ||||
5 | B-cell lymphoma [ICD-11: 2A86] | ||||
6 | Asthma [ICD-11: CA23] | ||||
7 | Multiple myeloma [ICD-11: 2A83] | ||||
8 | Inflammation [ICD-11: 1A00-CA43.1] | ||||
9 | Diffuse large B-cell lymphoma [ICD-11: 2A81] | ||||
Approved Drug(s) | 4 Approved Drugs | 4 | |||
1 | Tofacitinib | Approved | |||
2 | Pacritinib | Approved | |||
3 | Abrocitinib | Approved | |||
4 | Ritlecitinib | Approved | |||
Clinical Trial Drug(s) | 4 Clinical Trial Drugs | 4 | |||
1 | VX-509 | Phase 2/3 | |||
2 | ATI-502 | Phase 2 | |||
3 | Cerdulatinib | Phase 2 | |||
4 | GDC-0214 | Phase 1 | |||
Discontinued Drug(s) | 1 Discontinued Drug | 1 | |||
1 | AG490 | Terminated | |||
Investigative Drug(s) | 2 Investigative Drugs | 2 | |||
1 | PF-956980 | Investigative | |||
2 | WHI-P154 | Investigative |
Similar Protein(s) and Bioactivity Statistics
50% Identity
Protein ID | Protein Name | Protein Organism | |
PT05132 | Tyrosine-protein kinase JAK3 | Mus musculus, Mouse |
---|